Literature DB >> 30898959

Iatrogenic transverse myelitis in a patient with rheumatoid arthritis.

Pournamy Sarathchandran1, Ayman Alboudi2, Reem AlSuwaidi2, Abubaker AbdulRahman Almadani3.   

Abstract

We report the case of a 59-year-old Arab woman who was presented with acute onset of neck pain followed by quadriparesis, paraesthesias of lower limbs and incontinence of urine. Examination revealed asymmetric sensorimotor quadriparesis with sensory level at T1, establishing a clinical diagnosis of transverse myelitis. Cervical and thoracic spinal MRI showed enhancing T2/fluid attenuated inversion recovery (FLAIR) hyperintense lesion extending from C4 to C7 level in addition to long-segment lesion extending the whole of the spinal cord. She was known to have rheumatoid arthritis for the past 20 years and has been on etanercept for the past 8 years and methotrexate since past 3 years. Etanercept was stopped and she was treated with methylprednisolone followed by oral steroids and physiotherapy with which she had near complete recovery. © BMJ Publishing Group Limited 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  rheumatoid arthritis; unwanted effects / adverse reactions

Mesh:

Substances:

Year:  2019        PMID: 30898959      PMCID: PMC6453356          DOI: 10.1136/bcr-2018-227584

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  9 in total

1.  Etanercept induced multiple sclerosis and transverse myelitis.

Authors:  Nawar Al Saieg; Michael J Luzar
Journal:  J Rheumatol       Date:  2006-06       Impact factor: 4.666

Review 2.  Neurological involvement in patients with rheumatic disease.

Authors:  N Sofat; O Malik; C S Higgens
Journal:  QJM       Date:  2006-01-24

3.  Onset of multiple sclerosis associated with anti-TNF therapy.

Authors:  N L Sicotte; R R Voskuhl
Journal:  Neurology       Date:  2001-11-27       Impact factor: 9.910

4.  The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment.

Authors:  Ferdinand C Breedveld; Michael H Weisman; Arthur F Kavanaugh; Stanley B Cohen; Karel Pavelka; Ronald van Vollenhoven; John Sharp; John L Perez; George T Spencer-Green
Journal:  Arthritis Rheum       Date:  2006-01

Review 5.  Neurological adverse events associated with anti-tumor necrosis factor α treatment.

Authors:  Antonio G Tristano
Journal:  J Neurol       Date:  2010-05-22       Impact factor: 4.849

Review 6.  Biochemical and clinical aspects of methotrexate neurotoxicity.

Authors:  Sandra Vezmar; Achim Becker; Udo Bode; Ulrich Jaehde
Journal:  Chemotherapy       Date:  2003-05       Impact factor: 2.544

7.  Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides.

Authors:  N Mohan; E T Edwards; T R Cupps; P J Oliverio; G Sandberg; H Crayton; J R Richert; J N Siegel
Journal:  Arthritis Rheum       Date:  2001-12

8.  Pattern of demyelination occurring during anti-TNF-α therapy: a French national survey.

Authors:  Raphaèle Seror; Christophe Richez; Christelle Sordet; Stéphanie Rist; Laure Gossec; Guillaume Direz; Eric Houvenagel; Jean-Marie Berthelot; Christian Pagnoux; Emmanuelle Dernis; Sylvie Melac-Ducamp; Beatrice Bouvard; Caroline Asquier; Antoine Martin; Xavier Puechal; Xavier Mariette
Journal:  Rheumatology (Oxford)       Date:  2013-01-03       Impact factor: 7.580

9.  Myelitis and optic neuritis induced by a long course of etanercept in a patient with rheumatoid arthritis.

Authors:  Waka Yokoyama; Kazuki Takada; Nobuyuki Miyasaka; Hitoshi Kohsaka
Journal:  BMJ Case Rep       Date:  2014-08-01
  9 in total
  1 in total

Review 1.  Drug-related immune-mediated myelopathies.

Authors:  David Gritsch; Cristina Valencia-Sanchez
Journal:  Front Neurol       Date:  2022-09-29       Impact factor: 4.086

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.